Skip to main content
SpringerLink
Log in

It may be possible to prevent restenosis by targeting oxidative stress

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig 2.

References

  1. Kester M, Waybill P, Kozac M. New strategies to prevent restenosis. Am J Cardiovasc Drugs 2001; 1(2): 77–83

    Article  PubMed  CAS  Google Scholar 

  2. Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med 1999; 340: 115–26

    Article  PubMed  CAS  Google Scholar 

  3. Tardif JC, Grégoire J, L’Allier PL. Prevention of restenosis with antioxidants: mechanisms and implications. Am J Cardiovasc Drugs 2002; 2(5): 323–34

    Article  PubMed  CAS  Google Scholar 

  4. Christen WG, Hennekens CH. Antioxidant vitamins and cardiovascular disease: evidence from observational epidemiologic studies and randomized trials. In: Tardif JC, Bourassa MG, editors. Antioxidants and cardiovascular disease. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2000: 135–44

  5. Tardif JC, Côté G, Lespérance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997; 337: 365–72

    Article  PubMed  CAS  Google Scholar 

  6. Yokoi H, Daida H, Kuwabara Y, et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 1997; 30: 855–62

    Article  PubMed  CAS  Google Scholar 

  7. Rodés J, Tardif JC, Lespérance J, et al. Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation 1998; 97: 429–36

    Article  PubMed  Google Scholar 

  8. Edelman ER. Vessel size, antioxidants, and restenosis. Never too small, not too little, but often too late. Circulation 1998; 97: 416–20

    Article  PubMed  CAS  Google Scholar 

  9. Yokoi H, Daida H, Yamaguchi H, et al., for the PART Group. Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty in small coronary arteries: a subgroup analysis of the Probucol Angioplasty Restenosis Trial (PART) [abstract]. J Am Coll Cardiol 1997; 29: 418A

    Google Scholar 

  10. Meng CQ, Somers PK, Rachita CL, et al. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg Med Chem Lett. 2002 Sep 16; 12(18): 2545–8

    Article  PubMed  CAS  Google Scholar 

  11. McKeage K, Murdoch D, Goa KL. The sirolimus-eluting stent: a review of its use in the treatment of coronary artery disease. Am J Cardiovasc Drugs 2003; 3(3): 211–30

    Article  PubMed  Google Scholar 

  12. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized doubl-blind trial on a slow-release paclitaxel elluting stent for de novo coronary lesions. Circulation 2003 Jan; 107: 38–42

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

It may be possible to prevent restenosis by targeting oxidative stress. Drugs Ther. Perspect 19, 16–18 (2003). https://doi.org/10.2165/00042310-200319070-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319070-00006

Keywords

Search

Navigation